GLP-1 medicines linked to surgical benefits and hair loss risks

New research presents a complex picture of the effects of GLP-1 receptor agonists, which are widely used for diabetes and weight loss. A large-scale study of over two million adults in the United States suggests these medications may reduce post-surgical complications. The analysis, presented at the American Society of Anesthesiologists’ ANESTHESIOLOGY 2026 meeting, found that GLP-1 users had 11% lower odds of major heart and circulation-related complications, such as heart attack or stroke, and 8% lower odds of post-operative infections, including pneumonia and sepsis.

Conversely, research published in The BMJ indicates a significant association between GLP-1 medicines and alopecia. Adults with type 2 diabetes starting GLP-1 receptor agonists faced a 37% higher relative risk of hair loss compared to those using SGLT-2 inhibitors, and a 68% higher risk compared to those using DPP-4 inhibitors.

Medical experts, including Australian dermatologist Professor Rod Sinclair, noted that while the absolute risk remains low, it is unclear if the hair loss is caused directly by the drugs, the rapid weight loss itself, or associated nutritional deficiencies like inadequate protein and iron intake. The hair loss observed is often non-scarring, but there are concerns it could potentially trigger long-term androgenetic alopecia in susceptible individuals.